Commentary: how will interventional oncology navigate the "valleys of death" for new medical devices?

Area of Science:

• Interventional oncology
• Medical device development
• Clinical trial methodology

Background:

• Cancer drug trials have established standards, but loco-regional treatments and devices face unique challenges.
• Generating high-level clinical evidence for these novel approaches is crucial for patient benefit.
• Existing frameworks may not adequately assess the efficacy and safety of interventional oncology devices.

Purpose of the Study:

• To argue for the importance of a collective data package over single primary endpoints in evaluating loco-regional treatments.
• To propose supplementing limited clinical data with other evidence types.
• To address the challenges in the clinical development pathway for interventional oncology devices, including the "valley of death".

Main Methods:

• The study presents a conceptual argument based on the challenges in clinical development.
• It reviews the current landscape of evidence generation for loco-regional therapies and medical devices.
• It discusses the concept of the "valley of death" in medical innovation.

Main Results:

• The collective coherence of an entire data package is often more critical than a single trial's primary endpoint for demonstrating efficacy and safety.
• Limited clinical data can be effectively supplemented with other forms of evidence.
• A clear development pathway is essential for interventional oncology devices to overcome regulatory and market access hurdles.

Conclusions:

• A holistic approach to evidence generation is vital for interventional oncology devices.
• Addressing the "valley of death" requires planning beyond regulatory approval to include clinical acceptance and reimbursement.
• International guidance is needed to establish appropriate standards for evaluating these innovative treatments and devices.